HC Wainwright Issues FY2030 Earnings Forecast for Ocugen

Analysts predict $1.04 earnings per share for the biopharmaceutical company in 2030.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Stock analysts at HC Wainwright have issued their FY2030 earnings per share estimates for Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on gene therapies and vaccines. The firm's analyst S. Ramakanth anticipates that Ocugen will post earnings per share of $1.04 for the year 2030, compared to the current full-year consensus estimate of ($0.20) per share.

Why it matters

Ocugen's long-term earnings potential is of interest to investors as the company advances its pipeline of rare inherited retinal disease gene therapies and infectious disease vaccines. The FY2030 forecast provides insight into the company's projected financial performance and growth trajectory over the next decade.

The details

In a research report issued on Monday, March 9th, HC Wainwright analyst S. Ramakanth provided the FY2030 earnings per share estimate for Ocugen. The forecast comes as the company recently reported its Q4 2025 financial results, posting a loss of $0.06 per share, in line with analyst expectations.

  • The research report from HC Wainwright was issued on Monday, March 9th, 2026.
  • Ocugen last reported quarterly earnings on Wednesday, March 4th, 2026.

The players

Ocugen, Inc.

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Ocugen is headquartered in Malvern, Pennsylvania.

S. Ramakanth

An analyst at HC Wainwright who issued the FY2030 earnings forecast for Ocugen.

HC Wainwright

A stock research and investment banking firm that provides research coverage and analysis on Ocugen.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The FY2030 earnings forecast from HC Wainwright suggests Ocugen's gene therapy and vaccine programs could drive significant long-term growth for the company, though the estimates remain speculative this far out. Investors will closely monitor Ocugen's progress in advancing its pipeline and achieving profitability in the coming years.